Safety and efficacy of a novel AAV vector for treatment of hemophilia B

被引：0
|
作者：
Anguela, X. [1 ,2 ]
Toso, R. [2 ]
Couto, L. B. [2 ]
Chen, Y. [2 ]
Hui, D. [2 ]
DiPietro, M. [2 ]
Lee, B. [1 ]
Qu, G. [2 ]
Hauck, B. [2 ]
Corbau, R. [1 ,2 ]
Wright, F. [2 ]
High, K. A. [2 ]
机构：
[1] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[2] Spark Therapeut Inc, Philadelphia, PA USA
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2015年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO172-MON
引用
收藏
页码：324 / 325
页数：2
相关论文
共 50 条
  • [31] Comparison of treatment efficacy in the hypoglossal motor system of AAV-DES-coGAA and novel vector AAV-DES-IGFIIcoGAA in Gaa-/- mice
    Doyle, Brendan Michael
    Turner, Sara M. F.
    Poirier, Amy
    Jorgensen, Marda L.
    Falk, Darin J.
    Doerfler, Phillip A.
    Byrne, Barry J.
    Fuller, David D.
    FASEB JOURNAL, 2017, 31
  • [32] Treatment for Hemophilia B Using Self-Complimentary AAV8 Vectors
    Hebert, Micheal L.
    Grimm, Dirk
    Storm, Theresa A.
    Kay, Mark A.
    MOLECULAR THERAPY, 2006, 13 : S189 - S190
  • [33] Efficacy and Safety of Viral Vector Based Gene Therapy in Patients with Hemophilia a: A Systematic Review
    Aiman, Wajeeha
    Kazmi, Syeda Hafsa
    Saeed, Memoona
    Khan, Muhammad Imran
    Omar, Zainab
    Suleman, Muhammad
    Jamil, Taimoor
    Bhatti, Mahak Khadija
    Butt, Sigmone Khalid
    Zubair, Hina
    Supraja, A.
    Zafar, Maha
    Arooj, Yusra
    Ali, Muhammad Ashar
    BLOOD, 2022, 140 : 12992 - 12993
  • [34] A Dose-Escalating Preclinical Study to Determine the Efficacy, MED, and Safety of a Clinical Candidate Vector in a Mouse Model of Hemophilia B
    Wang, Lili
    White, John
    He, Zhenning
    Goode, Tamara
    McMenamin, Deirdre
    Draper, Christine
    Brown, Cassandra
    Chroscinski, Edward A.
    Kattenhorn, Lisa
    Wilmes, Gwen
    Clark, Reed
    Wadsworth, Samuel
    Wilson, James M.
    MOLECULAR THERAPY, 2016, 24 : S89 - S89
  • [35] Non clinical safety and efficacy of a recombinant AAV2/8 vector administered intravenously for treatment of mucopolysaccharidosis type VI
    Ferla, R.
    Alliegro, M.
    Dell'Anno, M.
    Marteau, J. B.
    Pouillot, S.
    Galimberti, S.
    Valsecchi, M. G.
    Zuliani, V.
    Auricchio, A.
    HUMAN GENE THERAPY, 2017, 28 (12) : A71 - A72
  • [36] Non-clinical Safety and Efficacy of an AAV2/8 Vector Administered Intravenously for Treatment of Mucopolysaccharidosis Type VI
    Ferla, Rita
    Alliegro, Marialuisa
    Marteau, Jean-Brice
    Dell'Anno, Margherita
    Nusco, Edoardo
    Pouillot, Severine
    Galimberti, Stefania
    Valsecchi, Maria Grazia
    Zuliani, Vincent
    Auricchio, Alberto
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2017, 6 : 143 - 158
  • [37] STEPS TOWARD IMPROVED SAFETY OF TREATMENT IN HEMOPHILIA-B
    GOLDSMITH, JC
    JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1993, 121 (03): : 370 - 371
  • [38] AAV as a Gene Transfer Vector for the Treatment of Neurological Disorders: Novel Treatment Thoughts for ALS
    Hester, Mark E.
    Foust, Kevin D.
    Kaspar, Rita W.
    Kaspar, Brian K.
    CURRENT GENE THERAPY, 2009, 9 (05) : 428 - 433
  • [39] Safety and Efficacy of New Nonacog Alfa Drug (Innonafactor) in Prophylactic Treatment in Patients with Severe and Moderate Hemophilia B
    Andreeva, Tatiana
    Zorenko, Vladimir Yu.
    Davydkin, Igor
    Konstantinova, Valeria
    Zalepukhina, Olga
    Klimova, Nina
    Mishin, Georgy
    Kurtov, Igor
    Shamina, Maria
    Fatenkova, Elena
    Gusyakova, Olga
    Shuster, Alexandr
    Kudlay, Dmitry
    Lukyanov, Sergey
    Borozinets, Anton
    Nikitin, Eugene
    Klykova, Ekaterina
    BLOOD, 2015, 126 (23)
  • [40] Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B
    Harding, TC
    Koprivnikar, KE
    Tu, GH
    Zayek, N
    Lew, S
    Subramanian, A
    Sivakumaran, A
    Frey, D
    Ho, K
    VanRoey, MJ
    Nichols, TC
    Bellinger, DA
    Yendluri, S
    Waugh, J
    McArthur, J
    Veres, G
    Donahue, BA
    GENE THERAPY, 2004, 11 (02) : 204 - 213
12345